An obligatory requirement in the retrovirallife cycle is the integration of the viral dsDNA into the hostchromosome, a process performed byviral integrase. The retroviral integrase is able to catalyse at least three discrete enzymatic steps. Two of these steps, 3' processing and DNA strand transfer, can be measured in an in vitro assay in the presence of a duplex oligonucleotide corresponding to the viral long terminal repeat, recombinant integrase and the divalent cations, Mg2+ or Mn 2 +. This assay provides an efficient means of testing integrase inhibitors. As part of our continuous effort in developing novel inhibitors we examined a series of 2-mercaptobenzenesulphonamides (MBSAs) for their inhibitory activity against human immunodeficiency virus type 1 (HIY-1) integrase. From the list of compounds tested in an assay specific for HIY-1 integrase, 26 compounds inhibited the 3' processing and strand transfer step with 50% inhibitory concentration (lC 50 ) values below 25 f.!M. All the thioether derivatives were inactive. These results were further compared with the ability of MBSAs to protect HIY-1-infected T4 lymphocyte CEM cells. Among 68 compounds tested, 27 exhibited antiviral activity in cell-based assays with therapeutic indices of 1-16. All the MBSAs with antiviral activity were also effective inhibitors of recombinant HIY-1 integrase.
Introduction
Human immunodeficiency virus type 1 (HIV-1) integrase (IN) is responsible for inserting viral DNA into host chromosomes and is known to be essential for effective viral replication (for recent reviews see Katz & Skalka, 1994; Pommier et al., 1997; Rice et al., 1996a) . Recently it has been suggested that retroviral integrases belong to a superfamily of polynucleotidyl transferases that includes the Mu transposase and the nucleases RNase Hand RuvC (Rice et al., 1996a) . No cellular counterpart ofIN has been identified. Thus, IN appears to be an attractive target for selective inhibition. During viral infection, IN catalyses two consecutive reactions. Initially, IN processes linear viral DNA by removing two nucleotides from each 3' end, leaving the recessed 3'-OH termini. This is followed by transesterification of phospho diester bonds in which a host DNA strand is cut, and the 5' end of the cut is joined to a processed viral 3' terminus. These two steps, known as 3' processing and DNA strand transfer, respectively, can be easily measured in an in vitro assay employing purified recombinant IN and a 21-mer duplex oligonucleotide corresponding to the US end of the HIV long terminal repeat sequence.
During the past several years numerous classes of IN inhibitors have been described Pommier et al., 1997) . Although diverse classes of compounds exhibit considerable potency against purified recombinant IN, the mechanism of inhibition is not well understood. Studies with hydroxylated aromatics have suggested that inhibition may be associated in part with the ability of the inhibitors to chelate the cationic metal (Mn 2+ or Mg2+) that is required for enzyme function (Fesen et a/., 1993 (Fesen et a/., , 1994 Pommier et al., 1997) . In a recent study, we described the inhibitory activity of several lichen acids and concluded that many of the effective inhibitors contain catechol, carboxylic acid or an aldehyde functional group adjacent to an aromatic alcohol. Several of these inhibitors potentially chelate metal ions. Although many effective IN inhibitors were identified in an isolated enzyme system against IN, with a few exceptions the majority of these inhibitors exhibited substantial toxicity in cellular assays against HIV-1-infected CEM cells.
At present, no X-ray crystal structure of an IN-drug complex is available. Therefore, we have explored several alternative strategies in identifying novel inhibitors ofIN. For example, in recent studies we employed molecular modelling methods to generate pharmacophores from a series of active compounds against IN Neamati et al., 1997b; Nicklaus et al., 1997) and used such pharmacophores to identify new classes of inhibitors. We also synthesized derivatives from lead compounds (Burke et al., 1995; Eich et al., 1996; Zhao et al., 1997a,b,c) . We have also used a photoaffinity probe (Drake et al., 1997) and identified a unique binding site on IN that is responsible for the inhibitory mechanism of mononucleotides such as AZT monophosphates (Mazumder et al., 1996a) and oligonucleotides (Mazumder et al., 1996b) . Additionally, we have screened large numbers of compounds from the National Cancer Institutes (NCI, Bethesda, Md., USA) antiviral drug screening repository that have shown activity in cellular assays against HIV-l. From these endeavours, several distinct classes of IN inhibitors have been identified and reviewed recently Pommier et al., 1997) .
Although they represent completely unrelated structures, the majority of these inhibitors share common structural features composed of two aryl units separated by a central linker . Frequently, a catechol moiety is required for increased potency. In situ oxidation of catechol units to reactive quinones was recognized to present a potential limitation to their utility as drugs. In an effort to decrease the quinone-forming potential among these agents a series of arylamides was synthesized where 1,2-or 1,4-dihydroxyl substitution patterns were eliminated (Zhao et a/., 1997b) . In a separate study, we identified several diarylsulphones as novel inhibitors ofIN and showed that other functionalities could replace hydroxyl groups, thus taking advantage of a class of compounds with reduced ability to form reactive quinone species . In spite of these facts, many of the reported inhibitors retained high cytotoxicity in cellular assays, suggesting a need for a more rigorous strategy to reduce the inherent toxicity associated with many of the inhibitors.
In order to provide further insight into the structural requirements for IN activity and cytotoxicity, we are testing compounds that show activity in the N<;I Antiviral Drug Screening Program. Herein, we have determined the anti-IN activity of a series of novel 2-mercaptobenzenesulphonamides (MBSAs).
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Materials and Experimental Procedures
Compounds
All of the compounds used in this study were obtained from the NCI chemical repository through the Drug Synthesis and Chemistry Branch. The MBSAs were originally submitted to the NCI for anticancer and anti-HIV testing by Z Brzozowski, Medical Academy of Gdansk, and were dissolved in DMSO prior to each experiment. The stock solutions were kept at -20°C.
Preparation of oligonucleotide substrates
The high-performance liquid chromatography-purified oligonucleotides AEl17 (5'-ACTGCTAGAGATTTT-CCACAC-3') and AE118 (5'-GTGTGGAAAATCTC-TAGCAGT-3') were purchased from Midland Certified Reagent Company (Midland, Tex., USA). The expression vector for the wild-type IN was a generous gift of T Jenkins and R Craigie (Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, Bethesda, Md., USA). To analyse the extent of 3' processing and strand transfer using 5'-end-Iabelled substrates, AE118 was 5'-end-labelled with T4 polynucleotide kinase (Gibco BRL) and [y_32P]ATP (Dupont-NEN). The kinase was heat inactivated, and AE117 was added to the same final concentration. The mixture was heated at 95°C, allowed to cool slowly to room temperature, and run on a G-25 Sephadex quick spin column (Boehringer Mannheim) to separate annealed double-stranded oligonucleotide from unincorporated label.
IN assays
The detailed in vitro assays used to study inhibitors were recently described elsewhere . In brief, IN was preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer [50 mM NaCI, 1 mM HEPES pH 7.5, 50 IlM EDTA, 50 IlM DTT, 10% glycerol (w/v), 7.5 mM MnCI 2, 0.1 mg mL-l, 10 mM 2-mercaptoethanol, 10% DMSO, and 25 mM MOPS pH 7.2] at 30°C for 30 min. Then, the 5'-end 32P-Iabelled linear oligonucleotide substrate (20 nM) was added, and incubation was continued for an additional 1 h. Reactions were quenched by the addition of an equal volume (16 ilL) of loading dye (98% deionized formamide, 10 mM EDTA, 0.025% xylene cyanol, 0.025% bromophenol blue). An aliquot (5 ilL) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate pH 8.3,2 mM EDTA, 20% acrylamide, 8 M urea). Gels were dried, exposed in a PhosphorImager cassette, and analysed with a Molecular Dynamics PhosphorImager. Inhibition (%) was calculated using the following equation:
where C, N, and D are the fractions of 21-mer substrate converted to 19-mer (3' processing product) or strand transfer products for DNA alone, DNA plus IN, and IN plus drug, respectively. The SO% inhibitory concentrations (IC so ) were determined by plotting the 10gIO of drug concentration versus percentage inhibition and identifying the concentration which produced an inhibition of SO%.
Anti-HIVassays in cultured cell lines
The anti-HIV drug testing performed at NCI is based on a protocol described by Weislow et al. (1989) . In brief, all compounds were dissolved in DMSO and diluted 1:100 in cell culture medium. Exponentially growing T4 lymphocytes (CEM cell line) were added at SOOO cells well'", Frozen virus stock solutions were thawed immediately before use, suspended in complete medium to yield the desired multiplicity of infection (approximately 0.1), and added to the microtitre wells, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compound served as a toxicity control, and infected and uninfected cells without the compound served as basic controls. Cultures were incubated at 37°C in a S% CO 2 atmosphere for 6 days. The (2,3-bis[2-methoxy-4-nitro-S-sulphophenyl] -2H-tetrazolium-S-carboxanilide inner salt was added to all wells, and cultures were incubated to allow formazan colour development by viable cells. Individual wells were analysed spectrophotometrically to quantify formazan production, and in addition were viewed microscopically for detection of viable cells and confirmation of protective activity.
Results
Sixty-eight novel MESAs were evaluated for their ability to inhibit IN-catalysed 3' processing and DNA strand transfer. We initially tested the anti-IN activity of the compounds that had antiviral activity. Some derivatives devoid of antiviral activity were also tested to determine the structure-activity relationship of the integrase inhibition by MESAs (Tables 1-3 ). Compounds were grouped into three classes: the substituted sulphonamides, compounds 1-43 (Table 1) , the C-S demethylated derivatives, compounds 44-54 (Table 2) , and the thioether series 55-68 (Table 3 ). For screening of these compounds, we initially evaluated the inhibitory activities of MESAs at 200 !lM in the IN assay. Only those compounds that exhibited more than SO% inhibition at 200 !!M were further tested at several concentrations to determine SO% inhibitory concentration (IC so ) values.
Compound 1 exhibited IC so values of 16.4 and 12.6 !lM against 3' processing and strand transfer respectively, and a therapeutic index (TI) value of >2.7 in CEM cells. Dimerization of compound 1 to a disulphide analogue (2) yielded a more potent inhibitor in the cell-based assaywith Antiviral Chemistry & Chemotherapy 8 (6) 2-Mercaptobenzenesulphonamides as inhibitors of HIV·l integrase a TI value of >16.5, without loss of potency against IN. In fact, the inhibitory potency of disulphide 2 was approximately 6 !lM in both IN and cell-based assays. Although the majority of the compounds presented in Table 1 were active in the cell-based assay, derivatives 7, 8, 19,20, and 30-33 were inactive and also non-toxic. Several other compounds, 9-11, 12, 15,24-26 were toxic without apparent protection of the infected cells. Interestingly, except in a few Cases, no significant loss or gain in potency was observed against IN (Table 1) for compounds with various aromatic substitutions (derivatives 1-14), and fused rings (derivatives 15-26).
Among the compounds containing a primary amine group (derivatives.27-43) compound 39 with an EC so (SO% effective concentration) of 25 !!M was the most potent antiviral in CEM cells.This compound also inhibited IN 3' processing and strand transfer with IC so values of 17.3±10.0 and 24.8±13.3 I-lM, respectively. However, the rest of the compounds (27-38, 40-43) exhibited moderate or no activity in the cell-based assays. The loss of activity observed for several of the derivatives presented in Table 1 could be due to their physicochemical and pharmacokinetic properties. However, no apparent structural features responsible for the difference in potency could be discerned. Derivatives 42 and 43 were toxic without apparent protection of the infected CEM cells. Interestingly, compounds 29 and 42 with IC so values of 9.4 and 3.7 I-lM for 3' processing, and 6.3 and 2.7 !!M for strand transfer, respectively, were potent against IN. In general the electronic and steric effects of the substituent did not impart a significant effect on the IN function, suggesting a structural flexibility for inhibition by this group of compounds. However, compounds containing N-triazolyl or benzotriazolyl substituents on the sulphonamide have consistently shown improved potency over other derivatives against purified IN.
Compounds with subtle modification of the benzene ring were also included in our study to determine the effect of the halogen substitution at position 4 and demethylation at position S on their inhibitory actions (derivatives 44-54). For example, replacement of the chloro group at C-4 with a fluorine or a hydrazine and replacement of C-S methyl group with a cyano, ester, amide or a hydrogen (Table 2 ) exerted only moderate changes in potency in both assays.
Protection of the 2-mercapto group by various aliphatic or aromatic substituents yielded the corresponding thioethers 55-68 (Table 3 ) with total loss in activity in both cell-based and anti-IN assays. The importance of a free mercapto group for activity against IN is in accord with our earlier observations for diarylsulphones (Neamati et aI., 1997c) . For example, the 3,3'-dinitro-4,4'-dimercaptodiphenyl sulphone was >SO times more potent than its corresponding 3,3'-dinitro-4,4'-dihydroxydiphenyl iagram of basic structure of the compounds listed is shown above the Table. bValues with standard deviations are from at least three independent experiments and the others are from two independent experiments. C Therapeutic index: TI = ICso/EC so' dCompound 2 is the dimeric disulphlde analogue of compound 1. eNT, not tested bValues with standard deviations are from at least three independent experiments and the others are from two independent experiments. cTherapeutic index: TI = ICso/EC so' dNT, not tested. bValues with standard deviations are from three independent experiments. 'Theropeunc index: Tlso=ICso/ECso dph, phenyl sulphone (Neamati et al., 199?c) .
As shown in Tables 1-3 (Tables 1 and 2 ) with various substituents on the sulphonamide group exhibited comparable potencies in the IN assay. By contrast, the substituted thioethers were inactive both in the antiviral and IN assays (Table 3) . Therefore, no dramatic change in potency was observed for compounds with different substituents as long as a free mercapto group was present.
Although all of the MBSAs tested that were active against HIV-l replication were also active against IN, a large number of MBSAs that were active in the in vitro IN assay exhibited no antiviral activity. This could be due to toxicity to the CEM cells, as observed for compounds with low IC so in the antiviral assay. Lack of antiviral activity could also be due to differential cell penetration or intracellular pharmacokinetics for compounds with high EC so values. Moreover, compounds that were active only in the IN assays could potentially target other cellular sites and in addition, some of the compounds could also target different sites in the HIV-llife cycle.
Several of the MBSAs reported in this study could potentially dimerize to their corresponding disulphides which resemble the inhibitors of HIV-l nucleocapsid protein (NCp?). Compound 2 is a dimer of 1 and was found to exhibit comparable anti-IN potency and better antiviral activity than 1 (Table 1) . Recently, Rice et al. (1995) and Tummino et al. (1996) reported that the disulphide benzamides exert an antiviral effect by inhibiting NCp?, through attack on the two zinc fingers and consequently ejecting zinc. Thus, we tested several aromatic disulphides in our in vitro assay against IN and the results are presented in Table 4 . Compounds 71 and 74-78, with moderate activity against the NCp? zinc finger (Rice et al., 1996b) , also exhibited moderate activity against IN. However, compounds 69,70,72, and 73, which were active or moderately active against the NCp? zinc finger, were inactive against IN (Table 4) .
Discussion
In our previous report we found a series of diarylsulphones and sulphonamides as inhibitors of IN . The present study demonstrates that compounds containing a mercapto group adjacent to a sulphonamide (MBSAs) are potent inhibitors of IN and that a number of such compounds also inhibit HIV-1 replication in CEM cells.Thus, compounds containing a free sulphydryl group (Tables 1 and 2 ) and aromatic disulphides (Table 4) , sulphonates or sulphonic acids , sulphones and sulphonamides inhibit IN at low micromolar concentrations.
A majority of previously identified IN inhibitors are hydroxylated aromatics and many inhibit several enzymes of both cellular as well as HIV origin. Thus, identification of a selective agent has been difficult. Recently, we have reported that certain dimeric coumarins possess both anti-IN and anti-protease activity (Mazumder et al., 1996c) . In addition, many of the compounds that inhibit gp120 binding to CD4 also are very effective inhibitors of IN (Mahmood et al., 1993; Neamati et al., 1997b; Robinson et al., 1996a,b) . Several polyhydroxylated aromatics are also effective inhibitors of HIV-1 RT (Nishizawa et al., 1989) and IN .
It is apparent from the results presented in this study that some of the MBSAs may target other steps in the HIV life cycle. The resemblance of some of these compounds to the inhibitors that bind to the HIV-1 nucleocapsid zinc finger domain is noteworthy. For example, Rice et al. (1995) and Tummino et al. (1996) reported that the disulphide benzamides exert an antiviral effect by inhibiting NCp7, through attack on the two zinc fingers and consequently ejecting zinc. The inhibitors of NCp7 prevent normal processing of Gag precursors resulting in the release of non-infectious virus particles (Turpin et al., 1996) . During the course of our study, Rice et al. (1996b) showed that the disulphide 2 inhibited the HIV-1 zinc finger of NCp7. However, when a series of aromatic disulphides (Table 4) was tested in our in vitro assay against IN, some exhibited moderate potency, but no direct correlation between anti-IN and anti-NCp7 was observed. These differences could be due to the nature of zinc binding motif in NCp7 versus IN. The NCp7 contains two distinct canonical zinc finger motifs (CCHC), whereas IN accommodates only one zinc binding region with highly conserved HHCC residues at the N terminus.
The most potent MBSA, as well as the one with the highest TI value, proved to be the dimeric derivative 2. It seems that the anti-HIV activity of 2 in cell-based assays is associated with a relatively high degree of structural specificity, since a variety of structural changes resulted in diminished activity. Although the mechanistic details for this specificity remain to be elucidated, these observations further support our previous findings that compounds containing a mercapto 494 group adjacent to a nitro group or a sulphone exhibit remarkable anti-IN activity, despite the loss of potency exhibited by their hydroxylated congeners . Cumulatively, our data support the notion that MBSAs are potential inhibitors of IN with antiviral activity in cell-based assays.
